What can we learn from EMPA-REG OUTCOME and LEADER trials Yan Xiaowei Authors Info & Affiliations Published: 2016 -09 -01 · DOI: 10.3760/cma.j.issn.0578-1426.2016.09.002916 55 0 0 1 0PDF下载摘要 自2006年雷米普利和罗格列酮降低糖尿病发生率评价(DREAM)试验 [ 1 ] 显示罗格列酮的降糖...
更加令人振奋的是,恩格列净心血管结局研究(Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose, EMPA-REG OUTCOME,以下简称EMPA-REG研究)结果显示,对比现有的标准治疗,恩格列净能显著降低具有高心血管风险的T...
EMPA-REG OUTCOMEBackground Loop diuretics (LD) relieve symptoms and signs of congestion due to heart failure (HF), but many patients prescribed LD do not have such a diagnosis. Aims and methods We studied the relationship between HF diagnosis, use of LD, and outcomes in four patient ...
About EMPA-REG OUTCOME® EMPA-REG OUTCOME® was a long-term, multicentre, randomised, double-blind, placebo-controlled trial of more than 7,000 patients from 42 countries with type 2 diabetes at high risk for cardiovascular (CV) events. The study assessed the effect of Jardiance® (10 ...
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardio- vascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526–34. 32. Jones BJ, Ta T, Bloom SR. Minireview: glucagon in stress and energy homeostasis. Endocrinology. 2012;153...
(EMPA-REG OUTCOME), the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, and the Trial to Evaluate ... J Thrasher - 《American Journal of Medicine》 被引量: 28发表: 2017年 Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes...
Fitchett D, Zinman B, Wanner C et al (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardio- vascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 37:1526–1534 7. Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin ...
The FDA requires that all diabetes drugs undergo testing for CV outcomes.Empagliflozinwas the first to demonstrate a CV benefit. HF outcomes are important in patients with diabetes because those with both conditions have a median survival of only 4 y...
Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “We are encouraged by this latest analysis of the EMPA-REG OUTCOME® trial, which suggests that empagliflozin has the potential to be a cost-effective treatment option for people with type 2 diabetes and diabetic...
The mechanism of action of empagliflozin in reducing the risk of adverse CV outcomes in the EMPA-REG OUTCOME trial is currently unknown, and various potential explanations have been suggested, including hemodynamic, metabolic, or hormonal effects (as discussed by Staels7 in this issue). Here, we...